Other languages Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Real-time Estimate Cboe BZX Other stock markets 10:25:34 2024-04-24 am EDT			5-day change	1st Jan Change
23.8 ^USD	+2.48%		+3.78%	+3.18%

Apr. 12	Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	MT
Apr. 04	Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	Apr. 12
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	Apr. 04
Aerovate Therapeutics Q4 Loss Widens	Mar. 25
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing	Mar. 21
Aerovate Therapeutics, Inc. Announces Board Changes	Mar. 06
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing	Dec. 08
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing	Nov. 30
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	Nov. 20
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Aerovate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Aerovate Therapeutics, Inc. Appoints Habib Dable as Member of Board of Directors	23-07-11
Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Aerovate Therapeutics, Inc. Announces Progress on IMPAHCT Global Phase 2b/Phase 3 Clinical Trial of AV-101 for Pulmonary Arterial Hypertension	23-03-29
Aerovate Therapeutics, Inc. Appoints Donald Santel To Its Board of Directors	23-01-23
Top Midday Gainers	22-12-12
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research	22-11-17
Insider Sell: Aerovate Therapeutics	22-11-14
Aerovate Therapeutics Reports Wider Q3 Net Loss	22-11-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Other languages

Filters